Blood-Brain Barrier: Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue.Astrocytoma: Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)Medulloblastoma: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.Glial Fibrillary Acidic Protein: An intermediate filament protein found only in glial cells or cells of glial origin. MW 51,000.Nervous System Neoplasms: Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.Central Nervous System Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.Cerebellar Neoplasms: Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)Hypothalamic Neoplasms: Benign and malignant tumors of the HYPOTHALAMUS. Pilocytic astrocytomas and hamartomas are relatively frequent histologic types. Neoplasms of the hypothalamus frequently originate from adjacent structures, including the OPTIC CHIASM, optic nerve (see OPTIC NERVE NEOPLASMS), and pituitary gland (see PITUITARY NEOPLASMS). Relatively frequent clinical manifestations include visual loss, developmental delay, macrocephaly, and precocious puberty. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2051)Hyperlipoproteinemia Type V: A severe type of hyperlipidemia, sometimes familial, that is characterized by the elevation of both plasma CHYLOMICRONS and TRIGLYCERIDES contained in VERY-LOW-DENSITY LIPOPROTEINS. Type V hyperlipoproteinemia is often associated with DIABETES MELLITUS and is not caused by reduced LIPOPROTEIN LIPASE activity as in HYPERLIPOPROTEINEMIA TYPE I .Peripheral Nervous System Neoplasms: Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Central Nervous System: The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges.Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.Leukemia, Lymphoid: Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Digestive System Neoplasms: Tumors or cancer of the DIGESTIVE SYSTEM.Neurosurgical Procedures: Surgery performed on the nervous system or its parts.Appointments and Schedules: The different methods of scheduling patient visits, appointment systems, individual or group appointments, waiting times, waiting lists for hospitals, walk-in clinics, etc.Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)Craniotomy: Any operation on the cranium or incision into the cranium. (Dorland, 28th ed)Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.Outpatient Clinics, Hospital: Organized services in a hospital which provide medical care on an outpatient basis.Magnetoencephalography: The measurement of magnetic fields over the head generated by electric currents in the brain. As in any electrical conductor, electric fields in the brain are accompanied by orthogonal magnetic fields. The measurement of these fields provides information about the localization of brain activity which is complementary to that provided by ELECTROENCEPHALOGRAPHY. Magnetoencephalography may be used alone or together with electroencephalography, for measurement of spontaneous or evoked activity, and for research or clinical purposes.Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Carboplatin: An organoplatinum compound that possesses antineoplastic activity.Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Stem Cells: Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Stem Cell Transplantation: The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Eye Neoplasms: Tumors or cancer of the EYE.Uveitis, Posterior: Inflammation of the choroid as well as the retina and vitreous body. Some form of visual disturbance is usually present. The most important characteristics of posterior uveitis are vitreous opacities, choroiditis, and chorioretinitis.Calcium Sulfate: A calcium salt that is used for a variety of purposes including: building materials, as a desiccant, in dentistry as an impression material, cast, or die, and in medicine for immobilizing casts and as a tablet excipient. It exists in various forms and states of hydration. Plaster of Paris is a mixture of powdered and heat-treated gypsum.Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.Uveitis: Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)Intraocular Pressure: The pressure of the fluids in the eye.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Uveitis, Anterior: Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced.Panuveitis: Inflammation in which both the anterior and posterior segments of the uvea are involved and a specific focus is not apparent. It is often severe and extensive and a serious threat to vision. Causes include systemic diseases such as tuberculosis, sarcoidosis, and syphilis, as well as malignancies. The intermediate segment of the eye is not involved.ConnecticutNeuroma, Acoustic: A benign SCHWANNOMA of the eighth cranial nerve (VESTIBULOCOCHLEAR NERVE), mostly arising from the vestibular branch (VESTIBULAR NERVE) during the fifth or sixth decade of life. Clinical manifestations include HEARING LOSS; HEADACHE; VERTIGO; TINNITUS; and FACIAL PAIN. Bilateral acoustic neuromas are associated with NEUROFIBROMATOSIS 2. (From Adams et al., Principles of Neurology, 6th ed, p673)Meningioma: A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)Neuroma: A tumor made up of nerve cells and nerve fibers. (Dorland, 27th ed)Gluconobacter: A genus of gram-negative, rod-shaped to ellipsoidal bacteria occurring singly or in pairs and found in flowers, soil, honey bees, fruits, cider, beer, wine, and vinegar. (From Bergey's Manual of Determinative Bacteriology, 9th ed)Radiosurgery: A radiological stereotactic technique developed for cutting or destroying tissue by high doses of radiation in place of surgical incisions. It was originally developed for neurosurgery on structures in the brain and its use gradually spread to radiation surgery on extracranial structures as well. The usual rigid needles or probes of stereotactic surgery are replaced with beams of ionizing radiation directed toward a target so as to achieve local tissue destruction.Neurosurgery: A surgical specialty concerned with the treatment of diseases and disorders of the brain, spinal cord, and peripheral and sympathetic nervous system.Genome-Wide Association Study: An analysis comparing the allele frequencies of all available (or a whole GENOME representative set of) polymorphic markers in unrelated patients with a specific symptom or disease condition, and those of healthy controls to identify markers associated with a specific disease or condition.Nerve Sheath Neoplasms: Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category.Leiomyosarcoma: A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)Histiocytoma, Malignant Fibrous: The most commonly diagnosed soft tissue sarcoma. It is a neoplasm with a fibrohistiocytic appearance found chiefly in later adult life, with peak incidence in the 7th decade.Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.Hemangiosarcoma: A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)Neurofibromatosis 1: An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).Neurofibroma: A moderately firm, benign, encapsulated tumor resulting from proliferation of SCHWANN CELLS and FIBROBLASTS that includes portions of nerve fibers. The tumors usually develop along peripheral or cranial nerves and are a central feature of NEUROFIBROMATOSIS 1, where they may occur intracranially or involve spinal roots. Pathologic features include fusiform enlargement of the involved nerve. Microscopic examination reveals a disorganized and loose cellular pattern with elongated nuclei intermixed with fibrous strands. (From Adams et al., Principles of Neurology, 6th ed, p1016)Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.Rhabdomyosarcoma: A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)

Second-line treatment for primary central nervous system lymphoma. (1/857)

Failure after first-line treatment was reported in 35-60% of immunocompetent patients with primary central nervous system lymphoma (PCNSL). There are currently no reports focusing on salvage therapy. This review analyses prognostic factors and the efficacy of salvage therapy by focusing on data from papers reporting results of first-line treatment in 355 cases. The study group consisted of 173 patients presenting treatment failure. The interval between failure and death (TTD) was compared for age at relapse (< or =60 vs. >60 years), type of failure (relapse vs. progression), time to relapse (< or =12 vs. >12 months) and salvage treatment (yes vs no). Median TTD was similar in younger and older patients (P = 0.09). Relapsed patients had a longer TTD than patients with progressive disease (P = 0.002). Early relapse led to a shorter TTD than late relapse (P = 0.005). Median TTD was 14 months for patients who underwent salvage therapy and 2 months for untreated cases (P<0.00001). A multivariate analysis showed an independent prognostic role for salvage therapy and time to relapse. Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule.  (+info)

Neurologic complications of systemic cancer. (2/857)

Neurologic complications occur frequently in patients with cancer. After routine chemotherapy, these complications are the most common reason for hospitalization of these patients. Brain metastases are the most prevalent complication, affecting 20 to 40 percent of cancer patients and typically presenting as headache, altered mental status or focal weakness. Other common metastatic complications are epidural spinal cord compression and leptomeningeal metastases. Cord compression can be a medical emergency, and the rapid institution of high-dose corticosteroid therapy, radiation therapy or surgical decompression is often necessary to preserve neurologic function. Leptomeningeal metastases should be suspected when a patient presents with neurologic dysfunction in more than one site. Metabolic encephalopathy is the common nonmetastatic cause of altered mental status in cancer patients. Cerebrovascular complications such as stroke or hemorrhage can occur in a variety of tumor-related conditions, including direct invasion, coagulation disorders, chemotherapy side effects and nonbacterial thrombotic endocarditis. Radiation therapy is the most commonly employed palliative measure for metastases. Chemotherapy or surgical removal of tumors is used in selected patients.  (+info)

Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors. (3/857)

PURPOSE: A prospective phase II study was initiated to assess the response rate, survival, and late effects of treatment in patients with newly diagnosed CNS germ cell tumors (GCT), using etoposide plus cisplatin followed by radiation therapy prescribed by extent of disease, histology, and response to chemotherapy. PATIENTS AND METHODS: Seventeen patients aged 8 to 24 years with histologically proven CNS GCT received etoposide (100 mg/m2/d) plus cisplatin (20 mg/m2/d) daily for 5 days every 3 weeks for four cycles, followed by radiation therapy. Nine patients had germinomas; eight had mixed GCT. Four patients (three with germinomas and one with mixed GCT) presented with leptomeningeal dissemination. RESULTS: Radiographically, 14 of 17 patients were assessable for response; 11 patients experienced complete regression, and three had major partial regression before radiation. Six of seven assessable patients with elevated CSF levels of alpha-fetoprotein or betahuman chorionic gonadotropin had normalization with chemotherapy alone; all normalized with combined chemotherapy and radiation therapy. All 17 patients are alive without evidence of disease (median follow-up, 51 months). One patient developed a relapse in the spinal leptomeninges and was rendered free of disease with spinal radiation more than 5 years ago. One patient developed carotid stenosis requiring surgery. Thus far, only minimal long-term deterioration in neurocognitive function has been detected as a consequence of protocol treatment. CONCLUSION: Conventional-dose intravenous chemotherapy with etoposide and cisplatin can effect tumor regression in a high proportion of patients with CNS GCT, including those with leptomeningeal metastases. Acute and long-term toxicities are acceptable. Progression-free survival and overall survival are excellent.  (+info)

Third International Meeting on von Hippel-Lindau disease. (4/857)

Five years after the identification of the von Hippel-Lindau (VHL) gene, physicians, scientists and concerned VHL family members met to review the current state of knowledge on the diagnosis and treatment of VHL and to summarize the latest information on the biochemistry of the VHL protein (pVHL). The NIH and University of Pennsylvania groups reported the detection of germ-line mutations in 100% (93 of 93) of VHL families studied. Several studies determined the frequency of VHL germ-line mutations in individuals with a single manifestation of VHL without a family history of VHL. National groups to improve the diagnosis and treatment of individuals with VHL disease have been established in Great Britain, Denmark, France, Holland, Italy, Japan, Poland, and the United States. Evidence for the existence of genes that modify the expression of VHL was presented. The VHL protein appears to have several distinct functions: (a) down-regulation of hypoxia-inducible mRNAs; (b) proper assembly of the extracellular fibronectin matrix; (c) regulation of exit from the cell cycle; and (d) regulation of expression of carbonic anhydrases 9 and 12.  (+info)

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. (5/857)

BACKGROUND: During the 1980s, the incidence of primary malignant brain and other central nervous system tumors (hereafter called brain cancer) was reported to be increasing among all age groups in the United States, while mortality was declining for persons younger than 65 years. We analyzed these data to provide updates on incidence and mortality trends for brain cancer in the United States and to examine these patterns in search of their causes. METHODS: Data on incidence, overall and according to histology and anatomic site, and on relative survival were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute for 1975 through 1995. Mortality data were obtained from the National Center for Health Statistics. Medicare procedure claims from the National Cancer Institute's SEER-Medicare database were used for imaging trends. Statistically significant changes in incidence trends were identified, and annual percent changes were computed for log linear models. RESULTS/CONCLUSIONS: Rates stabilized for all age groups during the most recent period for which SEER data were available, except for the group containing individuals 85 years of age or older. Mortality trends continued to decline for the younger age groups, and the steep increases in mortality seen in the past for the elderly slowed substantially. Patterns differed by age group according to the site and grade of tumors between younger and older patients. During the last decade, use of computed tomography scans was relatively stable for those 65-74 years old but increased among those 85 years old or older. IMPLICATIONS: Improvements in diagnosis and changes in the diagnosis and treatment of elderly patients provide likely explanations for the observed patterns in brain cancer trends.  (+info)

V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. (6/857)

Primary central nervous system lymphoma (PCNSL) represents 1% to 3% intracranial tumors. Most PCNSL are located in the brain, and 75% are large B-cell lymphomas. The largest subgroup of these tumors contains cells that resemble centroblasts and has been labelled diffuse centroblastic (polymorphous) lymphoma. To investigate the cell of origin and the clonal history of these tumors, we have analyzed V(H) gene of 5 cases of PCNSL, all confirmed by histological studies to be Epstein-Barr virus (EBV)-negative, high-grade diffuse B-cell lymphomas. The V4-34 gene of the V(H)4 family was used in 4 of 5 cases. All V(H) genes were found to have accumulated very high levels of somatic mutation (14% to 25%). In 3 of 5 cases, intraclonal nucleotide heterogeneity, including codon deletion in some clones in 1 case, was observed, indicating that the V(H) genes were still under the influence of the somatic hypermutation mechanism. Analysis of the distribution of silent and replacement mutations showed evidence for preservation of immunoglobulin structure in all cases. These results suggest that, although there is no evidence for germinal center formation in the brain tissue, PCNSL is derived from a B cell with features associated with location in a germinal center environment.  (+info)

Association of childhood cancer with factors related to pregnancy and birth. (7/857)

BACKGROUND: It has been hypothesized that risk factors of childhood cancers may already operate during the prenatal and neonatal period. Results of previous epidemiological studies have been inconsistent. METHODS: During 1992-1997 a large case-control study on childhood cancers and a variety of potential risk factors was conducted in Germany. Cases were ascertained by the German Childhood Cancer Registry. Each case was matched to a population-based control of the same age and gender, sampled from the district where the case lived at the date of diagnosis. For the analyses, 2358 cases and 2588 controls were available. RESULTS: Risk of childhood acute leukaemia increased with maternal age < or =20 years at time of delivery (odds ratio [OR] = 1.9, 95% CI: 1.1-3.2), lower (<2500 g: OR = 1.7, 95% CI: 1.1-2.8) and higher birthweight (>4000 g: OR = 1.4, 95% CI: 1.0-1.8, P < 0.05), and hormonal treatment because of infertility (OR = 1.6, 95% CI: 1.0-2.5, P < 0.05). No associations were seen for parental smoking habits, maternal alcohol consumption during pregnancy and fetal losses. Parity was associated only with subgroups of acute leukaemias. Regarding non-Hodgkin's lymphoma we observed an elevated OR for lower birthweight and heavy maternal smoking during pregnancy (>20 cigarettes/day) and a decreased OR for children with one or two siblings. Only a few significant findings were seen for the different groups of solid tumours. CONCLUSIONS: Overall, only weak associations were identified and the evaluated risk factors operating during the neonatal and prenatal period account at most for only a small proportion of childhood cancers.  (+info)

Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse. (8/857)

Isolated extramedullary relapse in childhood acute lymphoblastic leukemia (ALL) may be accompanied by occult bone marrow disease. We used a highly sensitive assay to quantify leukemic progenitor cells (LPCs) in the bone marrow of such patients. Multiparameter flow cytometry and blast colony assays were used to detect LPCs in the bone marrow of 31 pediatric B-lineage ALL patients with an isolated extramedullary first relapse. Sites of relapse were central nervous system (22 patients), testes (7 patients), and eye (2 patients). Bone marrow (BM) LPC counts ranged from 0/10(6) mononuclear cells (MNCs) to 356/10(6) MNCs (mean +/- SE, 27.8+/-13.1/10(6) MNCs). LPCs were undetectable in 19 patients (61%). The BM LPC burden at the time of extramedullary relapse was similar, regardless of site (Wilcoxon P = 0.77) or time of relapse (Wilcoxon P = 0.80). Compared with higher risk, standard risk at initial diagnosis showed a trend for increased BM LPC burden (mean +/- SE, 44.6+/-17.1 versus 7.5+/-3.3; Wilcoxon P = 0.22). After successful postrelapse induction chemotherapy, LPC counts in 21 evaluated patients ranged from 0/10(6) to 175/10(6) MNCs (mean +/- SE, 15.9+/-9.6/10(6) MNCs). By comparison, LPC burden was higher after successful induction chemotherapy among children with an early BM relapse (range, 0 to 3262/ 106 MNC; mean +/- SE, 166+/-107; Wilcoxon P = 0.11). Thus, not all patients with an extramedullary relapse have occult systemic failure with substantial involvement of the bone marrow, and after reinduction therapy, LPC counts were lower in these patients than in patients treated for an overt BM first relapse.  (+info)

*Glioblastoma

"A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option". ... However, metastasis of GBM beyond the central nervous system is extremely unusual. About 50% of GBMs occupy more than one lobe ... It is the second most common central nervous system cancer after meningioma. The term glioblastoma multiforme was introduced in ... Stevens, Glen H. J. (2006). "Antiepileptic therapy in patients with central nervous system malignancies". Current Neurology and ...

*Precocious puberty

Central precocious puberty can be caused by intracranial neoplasm, infection (most commonly central nervous system tuberculosis ... Causes of central precocious puberty can include: damage to the inhibitory system of the brain (due to infection, trauma, or ... 2013). "Central precocious puberty caused by mutations in the imprinted gene MKRN3". N Engl J Med. 368: 2467-2475. doi:10.1056/ ... 2014). "Central precocious puberty that appears to be sporadic caused by paternally inherited mutations in the imprinted gene ...

*Lesional demyelinations of the central nervous system

They look like intracranial neoplasms, and sometimes they get biopsied as suspected tumors. Proton MR spectroscopy can help in ... However, in a person with MS, these cells recognize healthy parts of the central nervous system as foreign and attack them as ... Multiple sclerosis and other demyelinating diseases of the central nervous system (CNS) produce lesions (demyelinated areas in ... "Demyelinating diseases of the central nervous system". Medicine. 11 (77): 4601-4609. doi:10.1016/j.med.2015.04.001. Poser C. M ...

*List of MeSH codes (C04)

... bone marrow neoplasms MeSH C04.588.531.500 --- mammary neoplasms, experimental MeSH C04.588.614.250 --- central nervous system ... pituitary neoplasms MeSH C04.588.614.250.387 --- central nervous system cysts MeSH C04.588.614.250.387.100 --- arachnoid cysts ... peripheral nervous system neoplasms MeSH C04.588.614.596.240 --- cranial nerve neoplasms MeSH C04.588.614.596.240.015 --- ... central nervous system MeSH C04.557.645.375.850 --- sturge-weber syndrome MeSH C04.557.645.380 --- hemangiopericytoma MeSH ...

*D33

... a Almirante Clemente class destroyer the ICD-10 code for a benign neoplasm of brain and other parts of central nervous system ...

*D43

... the ICD-10 code for a neoplasm of uncertain or unknown behaviour of brain and central nervous system Semi-Slav Defense chess ...

*ICD-10 Chapter II: Neoplasms

Benign neoplasm of meninges (D33) Benign neoplasm of brain and other parts of central nervous system (D34) Benign neoplasm of ... Overlapping lesion of brain and other parts of central nervous system (C72.9) Central nervous system, unspecified (C73) ... Neoplasm of uncertain or unknown behaviour of brain and central nervous system (D44) Neoplasm of uncertain or unknown behaviour ... Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system (C72.0) Spinal cord (C72.1) Cauda ...

*Acute myeloid dendritic cell leukemia

Infrequently, other soft tissues and organ systems such as central nervous system, lung etc can be involved. A few cases of ... Kaur V (2016). "A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre- ... They process antigen material and present it on the surface to other cells of the immune system. Dendritic cells develop from ... 2016). "A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment ...

*List of ICD-9 codes 140-239: neoplasms

Primary central nervous system lymphoma (200.6) Anaplastic large cell lymphoma (200.7) Large cell lymphoma (200.8) Other named ... Benign neoplasm of eye (225) Benign neoplasm of brain and other parts of nervous system (226) Benign neoplasm of thyroid glands ... Malignant neoplasm of brain (192) Malignant neoplasm of other and unspecified parts of nervous system (192.0) Cranial nerve ( ... Neoplasm of uncertain behavior of endocrine glands and nervous system (237.0) Pituitary gland and craniopharyngeal duct ...

*Malignant rhabdoid tumour

Weeks and associates reported on 111 renal rhabdoid cases of which 13.5% also had a central nervous system malignancy. It has ... MRTs are a rare and highly malignant childhood neoplasm. Later rhabdoid tumours outside the kidney were reported in many ... PJ Biggs; Garen PD; Powers JM; Garvin AJ (1987). "Malignant rhabdoid tumor of the central nervous system". Hum Pathol. 18 (4): ... and the central nervous system. Several cases of primary intracranial MRT have been reported since its recognition as a ...

*WHO classification of tumours of the central nervous system

3.4 Other neoplasms related to the meninges 3.4.1 Haemangioblastoma (ICD-O 9161/1, WHO grade I) 4.1 Malignant Lymphomas (ICD-O ... Grading of the tumors of the central nervous system See the article Grading of the tumors of the central nervous system. Louis ... WHO pathology of tumours of central nervous system-2007 Zülch, Histological typing of tumours of the central nervous system. ... version of the last 2007 WHO classification of the tumours of the central nervous system. Currently, as of 2016, clinicians are ...

*C72

... cranial nerves and other parts of central nervous system ICD-10 code Siemens C72, a mobile phone Honda C71, C76, C72, C77 Dream ... C72 may refer to : Ruy Lopez chess openings ECO code Malignant neoplasm of spinal cord, ...

*List of ICD-9 codes 320-359: diseases of the nervous system

Central pain syndrome (338.1) Acute pain (338.2) Chronic pain (338.3) Neoplasm related pain (acute) (chronic) (338.4) Chronic ... Other demyelinating diseases of central nervous system (341.0) Neuromyelitis optica (341.1) Schilder's disease (341.2) Acute ... Other and unspecified disorders of the nervous system (349.0) Headache, post spinal puncture Post dural puncture headache ( ... 349.8) Other specified disorders of nervous system (349.81) Cerebrospinal fluid rhinorrhea (349.82) Toxic encephalopathy (350) ...

*Altered level of consciousness

Infections of the central nervous system may also be associated with decreased LOC; for example, an altered LOC is the most ... Neoplasms within the intracranial cavity can also affect consciousness, as can epilepsy and post-seizure states. A decreased ... Scheld WM, Whitley RJ, Marra CM (2004). Infections of the Central Nervous System. Hagerstown, MD: Lippincott Williams & Wilkins ... Since this system is thought to modulate wakefulness and sleep, interference with it, such as injury, illness, or metabolic ...

*List of MeSH codes (C10)

... hypothalamic neoplasms MeSH C10.551.240.250.700.500.500 --- pituitary neoplasms MeSH C10.551.240.375 --- central nervous system ... central nervous system MeSH C10.228.140.300.850.125 --- aids arteritis, central nervous system MeSH C10.228.140.300.850.250 ... central nervous system MeSH C10.500.190.600 --- central nervous system venous angioma MeSH C10.500.190.800 --- sinus pericranii ... central nervous system MeSH C10.114.875.350 --- lupus vasculitis, central nervous system MeSH C10.114.875.700 --- temporal ...

*Thrombolysis

History of stroke, dementia, or central nervous system damage within 1 year Head trauma within 3 weeks or brain surgery within ... known intracranial arteriovenous malformation or previously known intracranial neoplasm Suspected recent (within 30 days) ... 6 months Known intracranial neoplasm Suspected aortic dissection Internal bleeding within 6 weeks Active bleeding or known ...

*John E. Pickering

Radiation on the Central Nervous System and Pituitary Gland of Macaque Monkeys A Study of 67 Brains and Spinal Cords and 77 ... Kent, S. P., & Pickering, J. E. (1958). Neoplasms in monkeys (Macaca mulatta): spontaneous and irradiation induced. Cancer, 11( ... Radiation on the Central Nervous System and Pituitary Gland of Macaque Monkeys A Study of 67 Brains and Spinal Cords and 77 ... The family were lifelong Methodists and members of the Central United Methodist Church of Albuquerque since 1989 when they ...

*Michael L. J. Apuzzo

He studied functional restoration in the central nervous system and performed North America's first human stereotactic cerebral ... he developed early refinements of microsurgical techniques for the management of intracranial neoplasms. Specifically, he ... The biological restoration of central nervous system architecture and function: part 1-foundations and historical landmarks in ... "Combined Modality Therapy of Central Nervous System Tumors". ISBN 9783540006275. Hoh DJ, Liu CY, Pagnini PG, Yu C, Wang MY, ...

*Headache

... headache evaluation may include CT scan or MRI in order to look for possible structural disorders of the central nervous system ... intracranial neoplasm, epileptic seizure or other types of disorders or diseases that are intracranial but that are not ... According to this system, there are 19 types of neuralgias and headaches due to different central causes of facial pain. ... associated with the vasculature of the central nervous system. ICHD-2 classifies headaches that are caused by the ingestion of ...

*List of cancer types

Nodal marginal zone B cell lymphoma Non-Hodgkin lymphoma Precursor B lymphoblastic leukemia Primary central nervous system ... Marginal zone B-cell lymphoma Mast cell leukemia Mediastinal large B cell lymphoma Multiple myeloma/plasma cell neoplasm ...

*Brain tumor

Of numerous grading systems in use for the classification of tumor of the central nervous system, the World Health Organization ... Neoplasms will often show as differently colored masses (also referred to as processes) in CT or MRI results. Benign brain ... The central nervous system cancer survival rate in children is approximately 60%. The rate varies with the type of cancer and ... Blood vessels enter the central nervous system through the perivascular space above the pia mater. The cells in the blood ...

*Topoisomerase inhibitor

... during pregnancy and elevated risk of childhood malignant central nervous system (CNS) tumours has been found. Human DNA ... Use of topoisomerase inhibitors for antineoplastic treatments may lead to secondary neoplasms because of DNA damaging ... coffee and tea consumption during pregnancy and childhood malignant central nervous system tumours: the ESCALE study (SFCE)". ... in aqueous system over a wide temperature range". Journal of Agricultural and Food Chemistry. 56 (8): 2694-701. doi:10.1021/ ...

*Fibrillary astrocytoma

... s arise from neoplastic astrocytes, a type of glial cell found in the central nervous system. They may ... because the borders of the neoplasm tend to send out tiny microscopic fibrillary tentacles that spread into the surrounding ...

*Medulloepithelioma

... was originally classified as the most primitive neoplasm of the Central Nervous System (CNS) by Bailey and ... Central nervous system medulloepithelioma a series of eight cases including two arising in the pons. J Neurosurg 1996;84:430-6 ... Pathology of tumors the nervous system, 5th ed. Baltimore: Williams & Wilkins 1989; pp. 247-51. Sato T, Shimoda A, Takahishi T ...

*Astroblastoma

The World Health Organization, a specialized agency that classifies abnormal tumors affecting the central nervous system and ... often mistaking astroblastoma with glial neoplasms, high-grade astrocytes, and embryonal neoplasms. However, the "bubbly" ... Calcification deriving from nervous system tumors is a rare quality in astroblastoma patients, but it is nonetheless easy to ... "Astroblastoma in a Child." Children Nervous System 24.2 (2008): 165-68. Sughrue, Michael E., Jay Choi, Martin Rutkowski, and ...

*Papillary tumors of the pineal region

Papillary tumors of the central nervous system and particularly of the pineal region are very rare and so diagnosing them is ... Papillary tumor of the pineal region (PTPR) is a recently described neoplasm that has been formally recognized in the 2007 ... WHO classification of tumours of the central nervous system, chapter 7, Eds: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, IARC ... in 2003 and were introduced in the World Health Organization (WHO) classification of Central Nervous System (CNS) in 2007. ...
TY - JOUR. T1 - LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. AU - Lossos, Chen. AU - Bayraktar, Soley. AU - Weinzierl, Elizabeth. AU - Younes, Sheren F.. AU - Hosein, Peter. AU - Tibshirani, Robert J.. AU - Sutton Posthumus, Jocelyn. AU - Deangelis, Lisa M.. AU - Raizer, Jeffrey. AU - Schiff, David. AU - Abrey, Lauren. AU - Natkunam, Yasodha. AU - Lossos, Izidore. PY - 2014/1/1. Y1 - 2014/1/1. N2 - Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients ...
TY - JOUR. T1 - Primary central nervous system lymphoma. T2 - Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. AU - Dabaja, Bouthaina S.. AU - McLaughlin, Peter. AU - Ha, Chul S.. AU - Pro, Barbara. AU - Meyers, Christina A.. AU - Seabrooke, Lee F.. AU - Wilder, Richard B.. AU - Kyritsis, Athanassios P.. AU - Preti, H. Alejandro. AU - Yung, W. K.Alfred. AU - Levin, Victor. AU - Cabanillas, Fernando. AU - Cox, James D.. PY - 2003/9/1. Y1 - 2003/9/1. N2 - BACKGROUND. The current study was performed to determine the maximum tolerated dose (MTD), toxicity, and outcome of infusional 5 bromo-2′-deoxyuridine (bromodeoxyuridine; BUdR) given with accelerated fractionation whole brain radiation therapy (WBRT) after chemotherapy for the treatment of primary central nervous system lymphoma (PCNSL). METHODS. Twelve patients with untreated and histologically confirmed PCNSL were entered on the study between 1994 and 1996. ...
RATIONALE: Antiviral drugs such as zidovudine and ganciclovir act against viruses and may be an effective treatment for HIV. Interleukin-2 may stimulate a persons white blood cells to kill lymphoma cells. Combining these treatments may be effective in treating AIDS-related primary central nervous system lymphoma.. PURPOSE: Phase II trial to study the effectiveness of combining zidovudine, ganciclovir, and interleukin-2 in treating patients who have AIDS-related primary central nervous system lymphoma. ...
Prediction of radiosensitivity in primary central nervous system germ cell tumors using dynamic contrast-enhanced magnetic resonance imaging
Prediction of radiosensitivity in primary central nervous system germ cell tumors using dynamic contrast-enhanced magnetic resonance imaging
Primary central nervous system lymphoma(PCNSL) is a rare kind of non-Hodgkin lymphoma. Rituximab combined with high-dose methotrexate, cytarabine and dexamethasone (R-MAD regimen) were reported effective for PCNSL patients. Rituximab can cause several side effects, including fever, chills and rigors. In this case report, we demonstrate rituximab-induced interstitial pneumonitis in a PCNSL patient who has been treated with R-MAD regimen. The patient recovered after treatment and she remains complete remission after following consolidation chemotherapy. Here is no report of potential fatal complications of Rituximab like interstitial pneumonitis nowadays in PCNSL patients. As Rituximab is widely used, physicians should raise their awareness of this rare complication and detect RTX-ILD in early stage.
TY - JOUR. T1 - Case-based review. T2 - Primary central nervous system lymphoma. AU - Korfel, Agnieszka. AU - Schlegel, Uwe. AU - Johnson, Derek R.. AU - Kaufmann, Timothy J. AU - Giannini, Caterina. AU - Hirose, Takanori. PY - 2017/1/1. Y1 - 2017/1/1. N2 - Primary CNS lymphoma (PCNSL) is a rare diffuse large B-cell lymphoma originating within the central nervous system. The overall incidence of PCNSL is rising, particularly in the elderly population. Immunosuppression is a strong risk factor, but most patients with this tumor are apparently immunocompetent. Diagnosis of PCNSL can be challenging. Non-invasive or minimally invasive tests such as ophthalmological evaluation and spinal fluid analysis may be useful, but the majority of patients require tumor biopsy for definitive diagnosis. Our knowledge concerning optimum treatment of PCNSL is fragmentary due to paucity of adequately sized trials. Most patients are now initially treated with high-dose-methotrexate-based chemotherapy alone, as the ...
This study will evaluate the usefulness of two tests in quickly distinguishing whether a patient with HIV infection and focal brain lesions (an injury in a specific area of the brain) has a rare type of cancer called primary central nervous system lymphoma (PCNSL), or a parasitic infection called toxoplasmic encephalitis.. Toxoplasmic encephalitis is caused by a parasite and can be treated with antibiotics. PCNSL (lymphoma of the brain or spinal cord) must be definitively diagnosed with a brain biopsy (removal of a small piece of brain tissue), and the treatment is radiation therapy and chemotherapy.. The tests under study for diagnosing PCNSL or toxoplasmic encephalitis are measurement of Epstein Barr virus (EBV) DNA in cerebrospinal fluid (CSF) and FDG-PET scan of the brain. EBV is often found in the CSF of people with PCNSL. The study also will compare the accuracy of two imaging techniques-TI-SPECT and FDG-PET-in distinguishing between toxoplasmosis and PCNSL.. Patients 18 years of age and ...
Although meningiomas are among the most frequent intracranial tumors, primary central nervous system lymphoma represents a rare variant of extranodal non-Hodgkin-type lymphoma. Here, we report on a 73-year-old man with 2 suspicious intracerebral lesions. Combined DOTATATE PET/CT identif...read more ...
Doctors at NYU Langone use blood testing, a neurological exam, and imaging tests to diagnose primary central nervous system lymphoma. Learn more.
BACKGROUND: Paternal occupational exposures have been proposed as a risk factor for childhood central nervous system (CNS) tumours. This study investigates possible associations between paternal occupational exposure and childhood CNS tumours in Great Britain. METHODS: The National Registry of Childhood Tumours provided all cases of childhood CNS tumours born and diagnosed in Great Britain from 1962 to 2006. Controls without cancer were matched on sex, period of birth and birth registration sub-district. Fathers occupations were assigned to one or more of 33 exposure groups. A measure of social class was also derived from fathers occupation at the time of the childs birth. RESULTS: Of 11 119 cases of CNS tumours, 5 722 (51%) were astrocytomas or other gliomas, 2 286 (21%) were embryonal and 985 (9%) were ependymomas. There was an increased risk for CNS tumours overall with exposure to animals, odds ratio (OR) 1.40 (95% confidence intervals (CIs) 1.01, 1.94) and, after adjustment for occupational
Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which malignant (cancer) cells from lymph tissue form in the brain and/or spinal cord (primary CNS) or spread from other parts of the body to the brain and/or spinal cord (secondary CNS). Because the eye is so close to the brain, primary CNS lymphoma can also start in the eye (called ocular lymphoma). The cancer can also involve the spinal fluid that bathes the spinal cord and brain. This is called leptomeningeal lymphoma. See Primary Central Nervous System Lymphoma for signs, symptoms and treatments.. ...
COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE
View details of top central nervous system lymphoma hospitals in Delhi NCR. Get guidance from medical experts to select best central nervous system lymphoma hospital in Delhi NCR
Response:. Our group published a microarray study of primary central nervous system lymphoma (PCNSL) in Blood in March 2008.1 We reported a comprehensive CNS signature of PCNSL, identifying single-gene differential expression as well as a pathway signature. Most notably, our pathway signature for PCNSL is characterized by differential expression of extracellular matrix (ECM)- and adhesion-related pathways. The most up-regulated gene is the ECM- and adhesion-related osteopontin (SPP1). Our study is unique in that we compared PCNSL to a broad spectrum of non-CNS diffuse large B-cell lymphoma (DLBCL), consisting of nodal and extranodal samples; and in-depth bioinformatics analysis was performed. This is in contrast to 2 other microarray studies in PCNSL2,3 in which the comparisons were made to nodal DLBCL and no pathway analysis was performed.. We are pleased that Rubenstein et al have confirmed our single-gene expression findings by retrospective analysis of their data and come up with concordant ...
Treatment for primary CNS lymphoma includes chemotherapy and often radiation therapy. Steroid therapy (e.g. dexamethasone) is often given before chemotherapy, as this helps reduce the swelling around the tumour, and may even shrink the tumour, reducing the raised intracranial pressure. Chemotherapy is given into a vein, and often also into the fluid surrounding the brain (intrathecally). Methotrexate is the drug most commonly given this way, and is also given in high doses intravenously- either on its own or in combination with other chemotherapy drugs and/or steroids. Radiotherapy uses high-energy rays to destroy the cancerous cells and can be an effective treatment for primary CNS lymphoma in younger people. It is used in combination with chemotherapy and steroid treatment. Surgery is only used to provide diagnostic tissue, and is never curative alone. Anticonvulsants may be given if seizures occur as a result of a tumour. If treatment is insufficient or if the disease recurs, some people are ...
Learn more about Childhood Central Nervous System Embryonal Tumors Treatment (PDQ®) (Patients) from the National Cancer Institute at Siteman Cancer Center.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. The main objective of this Cochrane review is to evaluate the role of additional chemotherapy to HD-MTX in the treatment of immunocompetent PCNSL patients with respect to overall survival (OS), progression-free survival (PFS), response rate, adverse events (AE), treatment-related mortality (TRM) and quality of life (QoL). ...
Clinical trial for Central Nervous System B-Cell Non-Hodgkin Lymphoma | CD20 Positive , Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response
Despite scarce data on surgical treatment of PCNSL, the efforts at resection are generally discouraged. This viewpoint is based on small-scale retrospective studies, which attests that surgical resection per se holds no clear advantages over supportive care. There are a few explanations as to what shaped this outlook. First, PCNSL is an infiltrative tumor with a multifocal nature, which can expand beyond the visible margin of the macroscopic lesion and has a predilection for early wide dissemination [50]. Second, the striking responsiveness to chemotherapy and radiotherapy might have alleviated the desire of invasive procedures against this type of tumor. Another reason could be the improvement of imaging studies, making surgical resection for histologic confirmation unnecessary. Finally, the postoperative morbidity in this patient population could have played a key role in discouraging surgical resection [51].. However, this mindset is not grounded on either randomized data or contemporary ...
The cell of origin of lymphomas arising in the CNS, a site devoid of normal resident lymphoid tissue, has not been determined. Morphological (4) , immunophenotypic (4) , and molecular genetic (5) studies of PCNSL suggest that the cell of origin is related to the GC. Expression of BCL-6 is one feature that suggests a relationship to the GC. The BCL-6 protein is a zinc-finger transcriptional repressor encoded by the BCL-6 gene (12) . It is required for the formation of the GC (13) . In normal lymphoid tissue, there is nuclear expression of the BCL-6 protein almost exclusively by GC B cells. Lymphomas thought to be derived from GC cells, such as follicular lymphoma, also express BCL-6, whereas lymphomas derived from naïve (chronic lymphocytic leukemia and mantle cell lymphoma) or post-GC (marginal zone lymphomas, myeloma) B cells do not (14 , 15) .. Additional immunophenotypic markers that can aid in the characterization of lymphoid cells with respect to stage of B-cell differentiation were ...
Primary central nervous system lymphoma is a rare neoplasm, exceptionally responsible for developing a frontal lobe syndrome. A 71-years-old patient with primary central nervous system lymphoma had undergone frontotemporal craniotomy for tumor removal. Month later, showing syncopies, disorientation and slurred speech, he was transported to Department of Internal Medicine. Neuroimaging revealed numerous tuberous changes in frontal and parietal lobes and frontotemporal area. During hospitalization, patient exhibited inadequate affect, jocular behaviour, was disoriented in the place and time, and unaware of his health state. He took repeated, uncritical attempts to jump out the window and started to exhibit persecutory delusions and hallucinations. Immediate brain radiotherapy was recommended by the oncology specialists. However, the patient did not consent to the recommended method of treatment due to his lack of recollection of the tumor or the craniotomy. The patient was forcibly transferred to ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
On page 3201 in the March 15, 2008, issue, the authors omitted the microarray data submission information and accession number. The following sentence should have appeared in "Results" as the first sentence of the first paragraph under the heading "Initial characterization of the microarray data": "We have deposited our microarray data in NCBIs Gene Expression Omnibus (Edgar et al, 2002) accessible through GEO Series accession number GSE11392 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE11392).". ...
Cardiology news, research and treatment articles offering cardiology healthcare professionals cardiology information and resources to keep them informed.
The present invention relates to primary CNS tumors and provides useful compositions and methods for reducing tumor volume and increasing the length of survival in mammals with primary CNS tumors, thereby providing a treatment for primary CNS tumors. The invention also relates to methods of identifying compounds for reducing tumor volume and increasing animal survival, which therefore relate to treating primary CNS tumors.
PAZZI, Paolo; TOMPKINS, Samantha and KIRBERGER, Robert M. Canine spirocercosis-associated extraskeletal osteosarcoma with central nervous system metastasis. J. S. Afr. Vet. Assoc. [online]. 2013, vol.84, n.1, pp.00-00. ISSN 2224-9435.. A five-year-old male Boerboel presented for examination, collapsed for an unknown period of time. On clinical examination, multifocal subcutaneous masses and enlarged prescapular lymph nodes as well as neurological deficits that suggested a multifocal neurological syndrome were found. Fine needle aspirates of the prescapular lymph nodes revealed cells suggestive of osteosarcoma. Radiographs showed foci of mineralisation within the soft tissue masses as well as diffuse pulmonary metastasis and a caudodorsal mediastinal mass believed to be a Spirocerca lupi nodule. Computed tomography imaging, necropsy and histopathology confirmed S. lupi oesophageal neoplastic transformation (extraskeletal osteosarcoma), believed to be the primary lesion, and the majority of ...
The following institutions and clinicians participated in the study: Hospital Universitari Germans Trias i Pujol, Badalona (J. M. Ribera, J. M. Sancho, A. Oriol, and E. Feliu); Hospital Carlos Haya, Malaga (C. Bethencourt); Hospital Virgen del Rocio, Sevilla (R. Parody); Hospital Virgen de la Victoria, Malaga (M. J. Moreno and M. J. Queipo de Llano); Hospital Clinico Universitario, Salamanca (J. M. Hernandez-Rivas); Hospital Clinico San Carlos, Madrid (E. del Potro); Hospital General, Alicante (C. Rivas and P. Fernandez-Abellan); Hospital Clinico Universitario, Valencia (M. Tormo and M. J. Terol); Hospital Son Dureta, Palma de Mallorca (J. Besalduch and A. Novo); Hospital Universitario La Fe, Valencia (M. A. Sanz and F. Moscardo); Hospital Xeral, Lugo (J. Arias); Hospital Morales Meseguer, Murcia (J. M. Moraleda and I. Heras); Hospital Vall dHebron, Barcelona (J. Bueno and J. J. Ortega); Hospital Clinico, Valladolid (J. Fernandez-Calvo and D. Borrego); Hospital Puerta del Mar, Cadiz (V. ...
In this retrospective multicentre study, we investigated the outcomes of elderly primary central nervous system lymphoma (PCNSL) patients (greater than or equal to65 years) who underwent high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) at 11 centres between 2003 and 2016. End points included remission, progression-free survival (PFS), overall survival (OS) and treatment-related mortality. We identified 52 patients (median age 68.5 years, median Karnofsky Performance Status before HDT-ASCT 80%) who all underwent thiotepa-based HDT-ASCT. Fifteen patients (28.8%) received HDT-ASCT as first-line treatment and 37 (71.2%) received it as second or subsequent line. Remission status before HDT-ASCT was: CR 34.6%, PR 51.9%, stable disease 3.8% and progressive disease 9.6%. Following completion of HDT-ASCT, 36 patients (69.2%) achieved CR (21.2% first-line setting and 48.1% second or subsequent line setting) and 9 (17.3%) PR (5.8% first-line setting and 11.5% second or subsequent
ON THIS PAGE: You will find some basic information about this disease and the parts of the body it may affect. This is the first page of Cancer.Nets Guide to Childhood Central Nervous System Tumors. Use the menu to see other pages. Think of that menu as a roadmap for this complete guide.
Purpose: Better understanding of the underlying biology of primary central nervous system lymphomas (PCNSL) is critical for the development of early detection strategies, molecular markers, and new therapeutics. This study aimed to define genes associated with survival of patients with PCNSL.. Experimental Design: Expression profiling was conducted on 32 PCNSLs. A gene classifier was developed using the random survival forests model. On the basis of this, prognosis prediction score (PPS) using immunohistochemical analysis is also developed and validated in another data set with 43 PCNSLs.. Results: We identified 23 genes in which expressions were strongly and consistently related to patient survival. A PPS was developed for overall survival (OS) using a univariate Cox model. Survival analyses using the selected 23-gene classifiers revealed a prognostic value for high-dose methotrexate (HD-MTX) and HD-MTX-containing polychemotherapy regimen-treated patients. Patients predicted to have good ...
TY - JOUR. T1 - False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. AU - Wiener, M. D.. AU - Boyko, Orest. AU - Friedman, H. S.. AU - Hockenberger, B.. AU - Oakes, W. J.. PY - 1990. Y1 - 1990. UR - http://www.scopus.com/inward/record.url?scp=0025093160&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0025093160&partnerID=8YFLogxK. M3 - Article. C2 - 2124036. AN - SCOPUS:0025093160. VL - 11. SP - 1100. EP - 1103. JO - American Journal of Neuroradiology. JF - American Journal of Neuroradiology. SN - 0195-6108. IS - 6. ER - ...
Primary central nervous system lymphoma (PCNSL) patients have a poorer prognosis than systemic lymphoma. Gain-of-function MYD88 c.794T , C (p. L265P) mutation and programed cell death-1 (PD-1) pathway alterations are potential targetable pathways. Our study objective was to determine th...read more ...
Bowers DC, Liu Y, Leisenring W, McNeil E, Stovall M, Gurney JG, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006 Nov 20;24(33):5277-82. Epub 2006 Nov 6.. Buckner JC, Brown PD, ONeill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc. 2007 Oct;82(10):1271-86.. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010 Mar;67(3):279-83.. Frei P, Poulsen AH, Johansen C, Olsen JH, Steding-Jessen M, Schüz J. Use of mobile phones and risk of brain tumours: update of Danish cohort study. BMJ. 2011 Oct 19;343:d6387. doi: 10.1136/bmj.d6387.. Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch Neurol. 2010 Mar;67(3):291-7.. INTERPHONE Study Group. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol. 2010 Jun;39(3):675-94. Epub ...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
When tumor progression occurs among patients with primary central nervous system (CNS) lymphomas, in which organ is tumor progression usually confined, according to the National Cancer Institutes PDQ® Information Summary for Health Professionals on primary CNS lymphoma treatment? ...
Survivors of central nervous system (CNS) tumours are particularly vulnerable to tumour- and treatment-related disability. We present the incidence of specific and overall functional and health-related late effects in a national adult survivor cohort. Diagnostic subgroups at particular risk for persistent sequels are identified. Data collection targeted 708 eligible ,18 years old survivors, 708 parent proxies and 1000 general population controls. Functional disability including sensory and cognitive impairment, emotional status and pain was assessed using the Health Utilities Index Mark 2/3 (HUI2/3). Survivors and controls, and diagnostic subgroups were contrasted to identify the general and relative risk for late effects by sub-diagnosis. Survivors had persistent late effects in sensation, mobility, self-care and cognition. Deficits in these domains indicated clinically important disability in overall health, although indices of emotion and pain were unaffected compared to controls. Late ...
The proportion of black or Hispanic patients with HIV-associated NHL increased from 41% in 2004 to 55% in 2012 (P < .0001). Chemotherapy was received by 81% of patients with diffuse large B-cell lymphoma, 90% of those with Burkitt lymphoma, 61% of those with primary effusion lymphoma (PEL), and 35% of those with primary central nervous system lymphomas (PCNSL). Between 2004 and 2012, this proportion increased only for patients with PCNSL (P < .00001). Chemotherapy was less likely to be received by patients who were older, black, or without private insurance. It was delivered more frequently in hospitals designated as academic (OR for nonreceipt, 0.68; 95% CI, 0.51-0.92) or in hospitals that had ≥3 HIV-positive cases per year (OR, 0.71; 95% CI, 0.58-0.86). Survival improved in patients with diffuse large B-cell lymphoma (P = .007), Burkitt lymphoma (P = .0002), and PCNSL (P = .019), but not in those with PEL (P = .94). Receipt of chemotherapy in patients with PEL was not associated with better ...
OBJECTIVE This is the final report of a phase III randomized study to evaluate whole-brain radiotherapy (WBRT) in primary therapy of primary CNS lymphoma (PCNSL) after a median follow-up of 81.2 months. METHODS Patients with newly diagnosed PCNSL were randomized to high-dose methotrexate (HDMTX)-based chemotherapy alone or followed by WBRT. We hypothesized that the omission of WBRT would not compromise overall survival (OS; primary endpoint), using a noninferiority design with a margin of 0.9. RESULTS In the per-protocol population (n = 320), WBRT nonsignificantly prolonged progression-free survival (PFS) (median 18.2 vs 11.9 months, hazard ratio [HR] 0.83 [95% confidence interval (CI) 0.65-1.06], p = 0.14) and significantly PFS from last HDMTX (25.5 vs 12.0 months, HR 0.65 [95% CI 0.5-0.83], p = 0.001), but without OS prolongation (35.6 vs 37.1 months, HR 1.03 [95% CI 0.79-1.35], p = 0.82). In the intent-to-treat population (n = 410), there was a prolongation by WBRT of both PFS (15.4 vs 9.9 ...
RESULTS: Primary CNSL was typically localized supratentorially (63%), with multiple (59%) or infiltrative (36%) lesions showing diffusion restriction (98%), often (87%) reaching the brain surface. In approximately 50% of patients, meningeal, ependymal or cranial nerve involvement was found. We detected significant differences in enhancement patterns between immunocompromised and immunocompetent patients; non-homogenous enhancement present in 50% of immunocompromised patients. We did not find any significant differences in MRI appearance between primary and secondary CNSL. Regression was evident after corticosteroid treatment in 52% of patients; however, in 16% of cases overall progression was observed ...
A 33-year-old male presented with a complaint of intermittently blurred vision and right facial weakness. MRI of the brain and orbits revealed numerous cranial nerve abnormalities. There were no focal brain or spinal cord lesions. Cerebral spinal fluid flow cytometry revealed a monoclonal population of B-lymphoid cells. No other evidence of disease was found. Serum Lyme antibody was reported to be IgM positive. Therapy with ceftriaxone, was followed by improvement in his symptoms. Although flow cytometry is a useful tool in distinguishing malignancy from inflammatory disorders it does not always establish the diagnosis of malignancy by itself.
Primary dural lymphoma (PDL) is a rare type of primary central nervous system lymphoma (PCNSL); however, its clinical etiology and appearance on magnetic resonance images (MRI) are similar to those of meningioma. We report a case of PDL mimicking a meningioma in the jugular tubercle, with hemiparesis and double vision, and review the published PDL case reports. A 41-year-old woman experienced numbness on her right side, and reported right hemiparesis and double vision 2 days thereafter. Her cranial computed tomography (CT) scan showed a mass lesion in the posterior fossa, and contrasted MRI revealed homogenous tumor with a dural tail sign in the left jugular tubercle ...
Primary CNS lymphomas (PCNSL) are relatively uncommon tumors, accounting for 2.5% of all brain tumors. By definition, there is no co-existing systemic disease at the time of diagnosis, distinguishing it from CNS involvement from systemic lymphoma...
This case report reviews the diagnosis, pathophysiology and management of primary central nervous system lymphoma, an aggressive non-Hodgkin lymphoma.
Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma Academic Article ...
True aqueductal tumors: a unique entity Anatomic features of glioblastoma and their potential impact on survival Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmatio Linear array ultrasound in low-grade glioma surgery:
MATERIALS AND METHODS: We retrospectively analyzed DSC-MR imaging of treatment-naïve, pathology-proved glioblastomas (n = 14), primary central nervous system lymphomas (n = 7), metastases (n = 20), and meningiomas (n = 13) using a protocol designed for relative CBV accuracy (a one-quarter-dose preload and single-dose bolus of gadobutrol, TR/TE = 1290/40 ms, flip angle = 60° at 1.5T). Mean percentage signal recovery, relative CBV, and normalized baseline signal intensity were compared within contrast-enhancing lesion volumes. Classification accuracy was determined by receiver operating characteristic analysis. ...
Thus, several efforts have focused on the development of further MR-based techniques including diffusion and perfusion imaging, and spectroscopy studies. 3). With this technique, magnetic field gradients are applied before and after the 180i pulse in spin echo imaging sequences. 3 Deep right basal ganglia primary central nervous system lymphoma characterized by a very low signal on T2 images (a), a sharp enhancement after gadolinium (b), and a clear restriction of apparent diffusion coefficient on diffusionweighted images (c) and maps (d). This implies that it is necessary to use methods that are sensitive and specific for the detection of hemorrhage. Both CT and MRI are useful for depicting the presence of hemorrhage, but the ability of CT to define its etiology is very poor. 35 Furthermore, the evolution of blood within tumor tissue may be slow, as compared to the evolution of benign hematomas. 35 The presence of non-hemorrhagic tumor tissue inside the lesion represents a clear sign of ...
Posted on 09/01/2006 6:32:30 PM PDT by mcg2000. (KDKA) PITTSBURGH Its the news people in Pittsburgh and beyond have been dreading; this afternoon, Dick Skrinjar announced that Mayor Bob OConnor has passed away. OConnor had been hospitalized since July 10th after learning that he suffered from a rare form of cancer called primary central nervous system lymphoma. On Monday, doctors downgraded the mayors condition after revealing that brain scans showed seizure activity and tests indicated an infection in his spinal fluid. The hospital stopped issuing updates on Mayor OConnors condition on Tuesday, which fueled rumors and speculation about his deteriorating condition. Sources told KDKA late Wednesday night that the mayor needed assistance breathing but was calm and peaceful. On Thursday afternoon, City Councilman Doug Shields confirmed that Mayor OConnor had been given the Sacrament of the Sick. Its basically a blessing for the sick. Its a Sacrament for the ill, Shields explained. ...
About NSCLC. Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-quarter of all cancer deaths, more than breast, prostate and colorectal cancers combined.3 Approximately 10-15% of patients in the US and Europe, and 30-40% of patients in Asia have EGFR mutation-positive (EGFRm) NSCLC.4,5,6 These patients are particularly sensitive to treatment with currently available EGFR-TKIs, which block the cell-signaling pathways that drive the growth of tumour cells.7 However, tumours almost always develop resistance to EGFR-TKI treatment leading to disease progression.8 Approximately half of patients develop resistance to approved EGFR-TKIs such as gefitinib and erlotinib due to the resistance mutation, EGFR T790M. Osimertinib also targets this secondary mutation that leads to disease progression.8,9 There is also a need for medicines with improved CNS efficacy, since approximately 25% of patients with EGFR-mutated NSCLC have brain metastases at diagnosis, ...
ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epide
Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor ...
A clinical trial is underway to examine the role of chimeric antigen receptor T-cell therapy for children and young adults with relapsed or refractory HER-2-positive central nervous system tumors. "[Although] survival rates have improved for pediatric …. Date : 2018-07-20T08:00:00.000 ...
TY - JOUR. T1 - DNA methylation-based classification of central nervous system tumours. AU - Capper, David. AU - Jones, David T W. AU - Sill, Martin. AU - Hovestadt, Volker. AU - Schrimpf, Daniel. AU - Sturm, Dominik. AU - Koelsche, Christian. AU - Sahm, Felix. AU - Chavez, Lukas. AU - Reuss, David E. AU - Kratz, Annekathrin. AU - Wefers, Annika K. AU - Huang, Kristin. AU - Pajtler, Kristian W. AU - Schweizer, Leonille. AU - Stichel, Damian. AU - Olar, Adriana. AU - Engel, Nils W. AU - Lindenberg, Kerstin. AU - Harter, Patrick N. AU - Braczynski, Anne K. AU - Plate, Karl H. AU - Dohmen, Hildegard. AU - Garvalov, Boyan K. AU - Coras, Roland. AU - Hölsken, Annett. AU - Hewer, Ekkehard. AU - Bewerunge-Hudler, Melanie. AU - Schick, Matthias. AU - Fischer, Roger. AU - Beschorner, Rudi. AU - Schittenhelm, Jens. AU - Staszewski, Ori. AU - Wani, Khalida. AU - Varlet, Pascale. AU - Pages, Melanie. AU - Temming, Petra. AU - Lohmann, Dietmar. AU - Selt, Florian. AU - Witt, Hendrik. AU - Milde, Till. AU - ...
Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.s profile, publications, research topics, and co-authors
We investigated the frequency, predictors, and evolution of acute lymphoblastic leukemia (ALL) in patients with CNS relapse and introduced a novel method for studying BCR-ABL1 protein variants in cDNA from bone marrow (BM) and cerebrospinal fluid (CSF) blast cells. A total of 128 patients were analyzed in two PETHEMA clinical trials. All achieved complete remission after imatinib treatment. Of these, 30 (23%) experienced a relapse after achieving complete remission, and 13 (10%) had an isolated CNS relapse or combined CNS and BM relapses. We compared the characteristics of patients with and without CNS relapse and further analyzed CSF and BM samples from two of the 13 patients with CNS relapse. In both patients, classical sequencing analysis of the kinase domain of BCR-ABL1 from the cDNA of CSF blasts revealed the pathogenic variant p.L387M. We also performed ultra-deep next-generation sequencing (NGS) in three samples from one of the relapsed patients. We did not find the mutation in the BM ...
UNLABELLED: The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age |10 years, progenitor-B cell disease, good-risk cytogenetics and those receiving Mitoxantrone. Adjusting for these variables (age, time to relapse, cytogenetics, treatment drug and gender) a multivariate analysis, showed a poorer outcome for those with combined CNS relapse (HR 2·64, 95% CI 1·32, 5·31, p = 0·006 for OS). ALL R3 showed an
Background: The peak incidence of central nervous system (CNS) tumors in childhood indicates that intrauterine or neonatal characteristics are potential risk factors or symptoms of early onset of disease.. Methods: We conducted a registry-based case-control study nested in the childhood populations of Denmark, Finland, Sweden, and Norway on the association between indicators of fetal growth and neonatal stress and childhood CNS tumor risk diagnosed during the period 1985-2006. Each of the 3,443 cases was matched individually on date of birth, sex, and country to five controls sampled randomly from population registries. Information on birth characteristics was obtained from national birth registries. We estimated odds ratios (OR) and 95% confidence intervals (95% CI) by conditional logistic regression analyses.. Results: We observed a U-shaped relation between risk for CNS tumors and birthweight, at ,4.5 kg (OR, 1.27; 95% CI, 1.03-1.55) and ,2.0 kg (OR, 1.50; 95% CI, 1.13-1.99), the latter being ...
Purpose of review: It is now fully clear that information on the molecular underpinnings of tumors of the central nervous system (CNS) can be used for a more robust characterization of at least selected neoplasms. During a meeting organized in Haarlem, The Netherlands, in May 2014, about 30 neuropathologists discussed how exactly molecular information could be incorporated in the routine classification of CNS tumors. Recent findings: This meeting laid the groundwork for an update of the WHO CNS tumor classification that integrates histopathological and molecular findings. Furthermore, a layered diagnostic approach was proposed that not only allows for integration of relevant molecular information in the pathological diagnosis, but also retains the option for rendering a diagnosis based on histopathological analysis alone. An integrated morphological and molecular definition of CNS tumors brings new challenges as well. For example, criteria for grading within molecularly defined categories of ...
From 1990 to 2001, more than 2 million doses of the vaccine were administered in the United States, followed by 1,850 reports to VAERS. About 6 percent of the reported events were listed as serious. Such events include those that result in death, hospitalization, permanent disability or are life-threatening. Reports of fatalities included two sudden cardiac arrests, one myocardial infarction, one aplastic anemia, one suicide and one central nervous system lymphoma ...
With great sorrow, NASW announces the death of its president, Laura van Dam, on April 24, 2006, after a long and courageous battle with central nervous system lymphoma.. An independent book editor, Laura spent many years as a senior editor with Houghton-Mifflin, where she specialized in books related to science, technology, medicine, and health. She worked with authors including Natalie Angier (Woman: An Intimate Geography), Daniel Schacter (The Seven Sins of Memory), J. Richard Gott (Time Travel Through Einsteins Universe), and Steve Olson (Mapping Human History, a National Book Award finalist).. Earlier in her career Laura served as a senior editor with the MIT publication Technology Review and as a newspaper reporter.. An NASW member for nearly 20 years, Laura was elected a board member in 1997 and became an officer in 1999. She assumed the responsibilities of NASW president in 2005 after serving as the associations secretary, treasurer, and vice president. Under Lauras leadership, NASW ...
Minneapolis fan Blue Petal (b.Louis Fallert 1950) died on February 16. Blue Petal suffered a stroke in December, following which he was diagnosed with central nervous system lymphoma. He began publishing Lous Apa in 1968, changing the name to Blues Apa when he took his nom de fan. In the 1970s, he joined Minneapa. He chaired Minicon 5 and co-chaired Minicon 7. He wa also an avid gamer, creating a gaming system called Castle Keep in the 70s.. ...
Minneapolis fan Blue Petal (b.Louis Fallert 1950) died on February 16. Blue Petal suffered a stroke in December, following which he was diagnosed with central nervous system lymphoma. He began publishing Lous Apa in 1968, changing the name to Blues Apa when he took his nom de fan. In the 1970s, he joined Minneapa. He chaired Minicon 5 and co-chaired Minicon 7. He wa also an avid gamer, creating a gaming system called Castle Keep in the 70s.. ...
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid (intrathecal chemotherapy), an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). The way the chemotherapy is given depends on where the tumor is in the CNS or eye. Primary CNS lymphoma may be treated with systemic chemotherapy, intrathecal chemotherapy and/or intraventricular chemotherapy, in which anticancer drugs are placed into the ventricles (fluid-filled cavities) of the brain. If primary CNS lymphoma is found in the eye, anticancer drugs are injected directly into the vitreous humor (jelly-like substance) inside the eye.. A network of ...
For those diagnosed with central nervous system metastases, treatment with trastuzumab, chemotherapy or surgery was each associated with a significant improvement in overall survival: trastuzumab 17.5 months vs. no trastuzumab 3.8 months; chemotherapy 16.4 months vs. no chemotherapy 3.7 months; and surgery 20.3 months vs. no surgery 11.3 months. "It is surprising that chemotherapy/trastuzumab adds to these womens survival," Brufsky said. "We thought that the brain metastases would be dominant in this regard no matter what therapy.". Follow the AACR on Twitter: @aacr #aacr Follow the AACR on Facebook: http://www.facebook.com/aacr.org. The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the worlds oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the ...
Background: Advances in pediatric cancer care which have improved outcomes in high-income countries have not reached the 80% of children with cancer who live in low-income countries. Efforts have been made to improve care for children with leukemia (the commonest childhood cancer) in low-income countries, but there has been virtually no focus on children with brain tumors (the second commonest childhood cancer). This study focused on Paraguay, a low-middle income country in South America. Only approximately 50% of the expected cases are diagnosed each year and of those, only 50% survive more than a few months after diagnosis. For children with central nervous system (CNS) tumors, preliminary data from two hospitals in Paraguay demonstrate that the number of children diagnosed with brain cancer is less than 50% of what is expected for the population based on global statistics. Patients that are referred for treatment have high morbidity and mortality. The goal of this study was to comprehensively ...
The patients included one female and four male subjects. Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma. The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two cases. The lymphoma was advanced (stage III or IV) in all patients. Four patients underwent surgical excision of the carcinoma and one patient was awaiting surgical treatment after completing systemic chemotherapy. Three subjects had high-grade carcinomas. Two patients had perineural invasion; one received adjuvant radiotherapy postoperatively but the other did not due to receiving systemic chemotherapy for recurrent NHL.. ...
Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma. Sub-category: Central Nervous System Tumors Category: Central Nervous System Tumors Meeting: 2017 ASCO Annual Meeting Abstract No: 2013 Poster Board Number: Poster Discussion Session (Board #255) Citation: J Clin Oncol 35, 2017 (suppl; abstr 2013) Author(s): Michael Weller, Martin Sill, Bettina Hentschel,…
Neoadjuvant chemotherapy used with neuroblastomas: Neuroblastomas are often large at presentation, and neoadjuvant chemotherapy is the preferred option, with the possibility of surgical resection for residual disease in groups with a high risk of progression based on residual disease or molecular biological factors (18). Additionally, surgery is used when there is neurological deterioration during treatment (8). Aydin et al. (2) showed no benefit in neurological outcome for patients with laminectomy in addition to systemic chemotherapy compared with those receiving chemotherapy alone. ...
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...
Gatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sánchez MJ, Lacour B, Kaatsch P, Berrino F, Rutkowski S, Botta L, EUROCARE-5 Working Group Eur J Cancer. 2017 Sep;82:137-148. doi: 10.1016/j.ejca.2017.05.028. Epub 2017 Jul 6.
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Brain biopsy is well established in clinical practice when there is suspicion of CNS malignancy. However, there is little consensus regarding the indications for brain biopsy in non-malignant neurological disease. This is due in no small part to limitations in the available literature pertaining to diagnostic brain biopsies. The published evidence largely comprises small, retrospective, single-centre analyses performed over long time periods, including non-homogeneous patient groups with considerable variation in reported outcomes. Here we present pragmatic guidance for those clinicians considering diagnostic brain biopsy in a patient with non-neoplastic neurological disease and highlight practice points with the aim of maximising the probability of gaining clinically useful information from the procedure. Full details in the University publications repository. ...
Methods Data from 224 patients of the CAMERA-II trial with monthly measurements of disease activity (DAS28) and BMI were used. Longitudinal regression (mixed model) analysis with BMI as dependent variable and DAS28 and treatment strategy as independent variables correcting for possible confounders (age, gender, rheumatoid factor, baseline BMI) was used. Separately, a longitudinal regression analysis with DAS28 as dependent variable and BMI and treatment strategy as independent variables, correcting for possible confounders was performed. To study the associations between disease activity and BMI several time lags between these variables were tested and the best fitting model was selected. To further focus on the longitudinal associations within patients an autoregressive model was used.. ...
This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care. ...
This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care. ...
Bladder cancer (BC) is the sixth most common cancer in the United States and is the number one cause of death among patients with urinary system malignancies ...
Named to the Top 10 Honor Roll on U.S. News & World Reports 2016-17 list of "Americas Best Childrens Hospitals," Nationwide Childrens Hospital is Americas largest not-for-profit freestanding pediatric healthcare system providing wellness, preventive, diagnostic, treatment and rehabilitative care for infants, children and adolescents, as well as adult patients with congenital disease. Nationwide Childrens has a staff of more than 11,000 providing state-of-the-art pediatric care during more than 1.2 million patient visits annually. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Childrens physicians train the next generation of pediatricians and pediatric specialists. The Research Institute at Nationwide Childrens Hospital is one of the Top 10 National Institutes of Health-funded freestanding pediatric research facilities. More information is available at NationwideChildrens.org ...
Investigator] Aghakhani N; Ali Benali M; Alliez B; Amat D; Amlashi A; Arbez-Gindre F; Arbion F; Assaker R; Aubriot Lorton MH; Auque J; Autricque A; Auvigne I; Averous G; Baldet P; Bataille B; Bazin A; Beaurain J; Benezech J; Bergemer Fouquet A; Besson G; Beuvon F; Billotet C; Blond S; Boetto S; Boissonnet H; Bonyhay G; Bouillot P; Bourgeois P; Bouvier C; Brassier G; Broche C; Brunon J; Cabal P; Cahn V; Caire F; Calvet P; Cazals-Hatem D; Chapon F; Chazal J; Civit T; Colnat S; Colombat M; Comoy J; Couvelard A; Czorny A; Dam Hieu P; Daumas-Duport C; Dautheribes M; David P; Debono B; Delage Corre M; Delhaye M; Delisle MB; Delsol G; Derlon JM; Desenclos C; Desplat A; Devaux B; Di Rocco F; Diaz A; Diebold MD; Dorfmuller G; Dran G; Dufour T; Dumas B; Dumollard JM; Durand L; Duthel R; Eimer S; El Fertit H; Emery E; Espagno C; Esposito P; Etchandy MP; Eyremandi RP; Faillot T; Felix S; Fernandez C; Fesselet J; Fontaine D; Fournier D; François P; Froelich S; Fuentes JM; Fuentes S; Gadan R; Gaspard C; Gay ...
TY - JOUR. T1 - Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies. AU - Choi, John. AU - Rui, Yuan. AU - Kim, Jayoung. AU - Gorelick, Noah. AU - Wilson, David R.. AU - Kozielski, Kristen. AU - Mangraviti, Antonella. AU - Sankey, Eric. AU - Brem, Henry. AU - Tyler, Betty. AU - Green, Jordan J.. AU - Jackson, Eric M.. PY - 2020/1. Y1 - 2020/1. N2 - Together, medulloblastoma (MB) and atypical teratoid/rhabdoid tumors (AT/RT) represent two of the most prevalent pediatric brain malignancies. Current treatment involves radiation, which has high risks of developmental sequelae for patients under the age of three. New safer and more effective treatment modalities are needed. Cancer gene therapy is a promising alternative, but there are challenges with using viruses in pediatric patients. We developed a library of poly(beta-amino ester) (PBAE) nanoparticles and evaluated their efficacy for plasmid delivery of a suicide gene therapy to pediatric brain cancer ...
Induction chemotherapy. High dose Methotrexate: The efficacy of Methotrexate in the treatment of Primary CNS lymphoma was first demonstrated by Ervin & Canellos in 1980 [17]. The primary CNS lymphoma cells inside brain are more sensitive to MTX and thus HD-MTX forms the backbone of PCNL therapy. HD-MTX is also shown a treatment related prognostic marker for survival in these patients [18]. There is no firm definition of HD-MTX and doses from 1g/m2 to 8 g/m2 has been reported in clinical trials [19]. Importantly Lippens and colleagues [20] demonstrated that intravenous administration of Methotrexate over 3 hours (3g/m2) leads to superior concentrations in cerebrospinal fluid (CSF) than infusion over 24 hours. Despite detectable meningeal disease in up to 15 % patients at diagnosis, intrathecal therapy has failed to achieve significantly better outcome [21]. Glantz et al demonstrated higher CSF levels after intravenous Methotrexate (8g/m2) than intrathecal injection with 12g/m2 Methotrexate [16]. ...
The results of genetic association studies regarding cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) polymorphisms and digestive system malignancies were controversial. The authors designed this meta-analysis to more precisely estimate relationships between CTLA-4 polymorphisms and digestive system malignancies by pooling the results of related studies. The authors searched PubMed, Embase, Web of Science, and CNKI for eligible studies. Thirty-one eligible studies were pooled analyzed in this meta-analysis. The pooled meta-analysis results showed that genetic distributions of rs231775, rs4553808, and rs733618 polymorphisms among patients with digestive system malignancies and controls differed significantly. Moreover, genotypic distribution differences were also observed for rs231775 polymorphism among patients with colorectal cancer/pancreatic cancer and controls, for rs4553808 and rs5742909 polymorphisms among patients with gastric cancer and controls, for rs3087243 polymorphism among patients
Retrospective, single-practice data analysis from a medical record system. Forty-one eyes of 31 patients, in which diagnostic or therapeutic vitrectomy was performed for VO between April 2012 and March 2015 in National Defense Medical College, were reviewed. Twelve eyes of 10 patients were infectious uveitis (males/females; 5/5, average age ± standard deviation; 71.8 ± 10.8 years old, primary top 3 diseases; endophthalmitis 5 eyes, cytomegalovirus retinitis 3 eyes, acute retinal necrosis 1 eye, ocular toxoplasmosis 1 eye), and 29 eyes of 21 patients were noninfectious uveitis (males/females; 3/18, average age; 64.0 ± 12.2 years old, primary top 3 diseases; sarcoidosis 9 eyes, primary central nervous system lymphoma 4 eyes, Behcets disease 2 eyes). BCVA before surgery and at 1, 3, and 6 months after surgery were converted to logMAR, and improvement rate of logMAR were evaluated by the ratio of postoperative logMAR to preoperative logMAR at the individual time points ...
The Oxford Textbook of Neuro-Oncology examines the epidemiology, pathogenesis, clinical features, and management of adult and childhood central nervous system (CNS) tumours. The book is organized according to the World Health Organization (WHO) classification of CNS tumours and includes an introductory chapter discussing the new, revised WHO classification that will be used in future editions of this textbook. The book reviews primary CNS tumours, metastatic CNS tumours, and familial tumour syndromes. Each chapter is organized according to a uniform framework, addressing epidemiology, aetiology, pathogenesis, clinical presentation, imaging, and treatment, with a focus on different treatment modalities and specific consideration of paediatric aspects, where applicable. Each chapter is authored by a multidisciplinary, international group of senior specialists representing the United States, Canada, Europe, and the Asia/Pacific region. It is written for generalists and specialists managing these ...
Objective. To describe the treatment and outcomes of patients with primary central nervous system (CNS) vasculitis. Methods. We retrospectively studied a cohort of 163 consecutive patients with primary CNS vasculitis who were seen at the Mayo Clinic over a 29-year period. We analyzed treatments, treatment responses, and factors predictive of outcomes. Results. A favorable response was observed in 85% of patients treated with prednisone alone and in 80% of patients treated with prednisone and cyclophosphamide. Relapses were observed in 27% of patients, and 25% of patients had discontinued therapy by the time of the last followup visit. Treatment with prednisone alone was associated with more frequent relapses (odds ratio [OR] 2.90), while large vessel involvement (OR 6.14) and cerebral infarcts at the time of diagnosis (OR 3.32) were associated with a poor response to treatment. Prominent gadolinium-enhanced cerebral lesions or meninges were linked with continued treatment at the last followup ...
TY - JOUR. T1 - Unilateral chronic relapsing primary central nervous system vasculitis. AU - Salvarani, Carlo. AU - Brown, R. D.. AU - Morris, J. M.. AU - Huston, J.. AU - Hunder, G. G.. PY - 2014. Y1 - 2014. UR - http://www.scopus.com/inward/record.url?scp=84901917691&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84901917691&partnerID=8YFLogxK. M3 - Letter. C2 - 24528778. AN - SCOPUS:84901917691. VL - 32. SP - S139-S140. JO - Clinical and Experimental Rheumatology. JF - Clinical and Experimental Rheumatology. SN - 0392-856X. IS - SUPPL.82. ER - ...
Central nervous system (CNS) lymphoma is a condition in which malignant cells are present in the lymph tissue of the brain and/or spinal cord. Treatment for CNS lymphoma generally does not include surgery. Instead, nonsurgical treatments, namely corticosteroids, chemotherapy and/or whole-brain radiation therapy, are used to treat CNS lymphoma.. Lymphoma designates a group of cancers that arise from white blood cells called lymphocytes. Because lymphocytes travel in the blood and lymph tissue and pass in and out of the CNS, lymphoma too can develop in various places in the body, including the CNS. CNS lymphoma is an aggressive type of lymphoma.. CNS lymphoma comes in two forms, depending on the origin of the tumor, and can produce single or multiple growths. ...
Primary central nervous system (CNS) lymphoma is a disease in which malignant (cancer) cells form in the lymph tissue of the brain and/or spinal cord. Lymphoma is a disease in which malignant (cancer) cells form in the lymph system. The lymph system is part of the immune system and is made up of the lymph, lymph...
CNS lymphoma refers to the involvement of the central nervous system with lymphoma. It can be broadly divided into primary and secondary, with a number of special types of also recognised. primary CNS lymphoma (PCNSL) intravascular lymphoma M...
Childhood central nervous system (CNS) germ cell tumors form from germ cells (a type of cell that forms as a fetus develops and later becomes sperm in the testicles or eggs in the ovaries). Learn about the signs, tests to diagnose, and treatment of pediatric germ cell tumors in the brain in this expert-reviewed summary.
Study 3 was a multicenter, open-label trial that randomized (1:1) patients with mCRC who were previously untreated in the metastatic setting and who had received no prior oxaliplatin to receive Panitumumab every 14 days in combination with FOLFOX or to FOLFOX alone every 14 days. Panitumumab was administered at 6 mg/kg over 60 minutes prior to administration of chemotherapy. The FOLFOX regimen consisted of oxaliplatin 85 mg per m2 IV infusion over 120 minutes and leucovorin (dl-racemic) 200 mg per m2 intravenous infusion over 120 minutes at the same time on day 1 using a Y-line, followed on day 1 by 5-FU 400 mg per m2 intravenous bolus. The 5FU bolus was followed by a continuous infusion of 5-FU 600 mg per m2 over 22 hours. On day 2, patients received leucovorin 200 mg per m2 followed by the bolus dose (400 mg per m2) and continuous infusion of 5FU (600 mg per m2) over 22 hours. Study 3 excluded patients with known central nervous system metastases, clinically significant cardiac disease, ...
AT/RTs are rare malignant intracranial tumors, representing only 1.3% of primary CNS tumors in the pediatric population and 6.7% of CNS tumors in children younger than 2 years.2 Malignant rhabdoid tumors can occur in many locations in the body, though the kidney and CNS are the most common primary sites.3 Within the CNS, 38%-65% have been reported to be infratentorial, 27%-62% in supratentorial locations, and 4%-8% occurring in multiple CNS sites at diagnosis.1,3,9. Rhabdoid cells in AT/RT observed with light microscopy are often plump with eccentric round nuclei containing prominent nucleoli within fibrillary or granular eosinophilic cytoplasm, though rhabdoid tumor cells can also be small and spindle-shaped with ovoid nuclei or large, containing nuclei with wrinkled margins.1,3,5,11 Abundant mitotic figures, necrosis, hemorrhage, and ill-defined margins with adjacent brain are common histologic feature seen in AT/RT.1,3,5,11 In addition to the rhabdoid tumor cells, intracranial AT/RTs often ...
The brain is the center of thought, memory, emotion, speech, sensation and motor function. The spinal cord and special nerves called cranial nerves carry and receive messages between the brain and the rest of the body. Brain tumors cause damage because, as they grow, they can interfere with surrounding cells that serve vital roles in our everyday life.. The Central Brain Tumor Registry of the United States estimates that more than 688,096 persons are living with a diagnosis of primary brain and central nervous system tumors in the United States.. An estimated 77,670 new cases of primary benign and malignant brain and central nervous system tumors are expected to be diagnosed in the United States in 2017.. ...
CSF cytology via lumbar puncture: If the primary tumor was exposed to the CSF compartment (or arose in it), lumbar CSF should be examined for cytology 7-14 days after surgery to exclude CSF dissemination unless there was preoperative evidence of leptomeningeal disease. ...
B cell monoclonal gene rearrangements have been reported in several cases of primary intraocular lymphoma and primary central nervous system lymphomas. Such molecular analysis has been performed on only one case of a primary testicular and a metastatic intraocular lymphoma. However, the gene rearrangements differed at the two sites. We present a case in which B cell monoclonality was found in an intraocular lymphoma and a primary breast lymphoma. Intraocular non-Hodgkins lymphomas are uncommon malignant tumours derived from two types of lymphomas; a primary central nervous system lymphoma (PCNSL) and a systemic lymphoma. Compared with primary intraocular lymphomas (PIOLs), the prevalence of metastatic systemic lymphomas is much lower.1 2 The diagnosis of … ...
FOSTER CITY, Calif. & SANTA MONICA, Calif.-(BUSINESS WIRE)-Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.. CAR T therapy is a breakthrough in hematologic cancer treatment in which a patients own T cells are engineered to seek and destroy cancer cells. CAR T therapy is manufactured specifically for each individual patient.. "The FDA approval of ...
Vemurafenib Recruiting Phase 2 Trials for Sarcoma, Osteogenic / BRAF NP_004324.2:p.V600X / Rhabdoid Tumors / Stage IV Childhood Non-Hodgkin Lymphoma / Recurrent Childhood Central Nervous System Neoplasm / Ependymomas / Recurrent Childhood Non-Hodgkin Lymphoma / Advanced Malignant Solid Neoplasm / Ewings Sarcoma (ES) / Stage III Childhood Non-Hodgkin Lymphoma / Malignant Gliomas / Soft Tissue Sarcoma (STS) / Hepatoblastomas / Malignant Germ Cell Tumor / Refractory Malignant Solid Neoplasm / Langerhans Cell Histiocytosis (LCH) / Recurrent Neuroblastoma / Histiocytosis / Recurrent Malignant Solid Neoplasm / Wilms tumor / Peripheral Primitive Neuroectodermal Tumor / refractory Non-Hodgkins lymphoma / Refractory Central Nervous System Neoplasm / Refractory Neuroblastoma / Rhabdomyosarcomas ...
TY - JOUR. T1 - Increased expression of osteopontin gene in atypical teratoid/rhabdoid tumor of the central nervous system. AU - Kao, Chung Lan. AU - Chiou, Shih Hwa. AU - Chen, Yann Jang. AU - Singh, Sher. AU - Lin, Han Tso. AU - Liu, Ren Shyan. AU - Lo, Chih Wen. AU - Yang, Chi Chang. AU - Chi, Chin Wen. AU - Lee, Chen Hsen. AU - Wong, Tai-Tong. PY - 2005/6/1. Y1 - 2005/6/1. N2 - The atypical teratoid/rhabdoid tumor, primary to the central nervous system, is a highly malignant and aggressive neoplasm of infancy and childhood. Although having distinct biological features and clinical outcomes, it is frequently misdiagnosed as primitive neuroectodermal tumor/medulloblastoma. To further distinguish the underlying pathogenesis and to identify biological markers for clinical use, an atypical teratoid/rhabdoid tumor-derived cell line was established and its gene expression pattern analyzed in comparison to the human astrocyte SVG12 cell line and the human DAOY medulloblastoma cell line using a ...
One classification system for lymphomas divides the diseases according to the size of the white blood cells that has turned cancerous. The large-cell lymphomas have large cells. A large cell, in this context, has a diameter of 17 to 20 µm. Other groups of lymphomas in this system are the small-cell lymphomas and mixed-cell lymphomas. Diffuse large B-cell lymphoma is the most common of the large-cell lymphomas. MeSH now classifies the phrase "large-cell lymphoma" under "Diffuse large B cell lymphoma". Many other B-cell lymphomas feature large cells: Angiocentric lymphoma Burkitts lymphoma Follicular large-cell lymphoma Immunoblastic lymphoma Intravascular large-cell lymphoma Primary mediastinal B-cell lymphoma T-cell-rich B-cell lymphoma Primary splenic lymphoma (rare) Primary central nervous system lymphomas, which are often diffuse large-B-cell lymphomas Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is believed to be caused by aberrant activation of a critical intracellular ...
In patients who had undergone surgery for brain metastases, the rate of recurrence at the resected site was similar between patients who received adjuvant whole-brain radiotherapy vs those who underwent adjuvant localized radiotherapy, according to a retrospective study by Hsieh et al in the journal Neurosurgery. However, localized radiotherapy was associated with a higher incidence of distant metastases.. Surgery followed by adjuvant whole-brain radiotherapy is a well-established treatment for brain metastases, particularly in patients who have a limited number of brain metastases. Yet discussions continue as to whether these patients require whole-brain radiotherapy or can be treated with localized radiotherapy. Localized radiotherapy is associated with fewer side effects compared with whole-brain radiotherapy, but some studies have documented an association with an increased risk for development of new intracranial metastases.. Thus, the investigators conducted a study to examine the rate of ...
0284] Although not wishing to be bound by any theory of operation, the inventors believe that the therapeutic agents of the invention ameliorate a number of conditions or illnesses, and especially reduce and/or eliminate cancer and/or the symptoms thereof by augmenting or stimulating the patients immune systems. In this sense, the invention is believed to be a form of biological therapy. As such, it is considered that the invention is applicable to virtually all cancers, such as the following: Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Childhood; Acute Myeloid Leukemia, Adult; Acute Myeloid Leukemia, Childhood; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; Adolescents, Cancer in; AIDS-Related Cancers; AIDS-Related Lymphoma; Anal Cancer; Appendix Cancer; Astrocytomas, Childhood; Atypical Teratoid/Rhabdoid Tumor, Childhood, Central Nervous System; Basal Cell Carcinoma; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bladder Cancer, Childhood; Bone Cancer, ...
Status: Recruiting. Condition Summary: Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant ...

Primary extracranial meningioma presenting as a forehead massPrimary extracranial meningioma presenting as a forehead mass

... of all intracranial neoplasms and is the second most common neoplasm of the central nervous system [1,2]. Meningiomas mainly ...
more infohttps://e-acfs.org/journal/view.php?number=566&viewtype=pubreader

LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma<...LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma<...

Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological ... abstract = "Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with ... N2 - Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with ... AB - Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with ...
more infohttps://miami.pure.elsevier.com/en/publications/lmo2-and-bcl6-are-associated-with-improved-survival-in-primary-ce

Central nervous system neoplasms drugs - New Doctor InsightsCentral nervous system neoplasms drugs - New Doctor Insights

Hoffman on central nervous system neoplasms drugs: Many drugs act on the brain, some because they are meant to, others as side ... Central nervous system neoplasms signs * Medicine for central nervous system neoplasms * Central nervous system neoplasms ... Brain & spinal cord: The central nervous system is made up of the brain and spinal cord. The peripheral nervous system is made ... that involves the central nervous system. Central nervous is composed of the brain and spinal cord. Myelin sheaths protect and ...
more infohttps://www.healthtap.com/topics/central-nervous-system-neoplasms-drugs

JoVE Search Results: Central Nervous System NeoplasmsJoVE Search Results: Central Nervous System Neoplasms

Adult primary central nervous system vasculitis. Abstract Mulvihill, John J. International Epidemiology Institute. 07/23/2010. ... Autoimmune T cell responses in the central nervous system. Abstract Ferretti, Patrizia. c/o Max-Planck Institute for Molecular ... Targeting protein kinases in central nervous system disorders. Abstract Branson, Helen M. University of Toronto. 11/06/2011. ... CXCL13 and CXCL12 in central nervous system lymphoma patients. Abstract Winer, Eric P. Dana-Farber Cancer Institute. 02/20/2009 ...
more infohttp://labindex.jove.com/group/Central-Nervous-System-Neoplasms

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms | Diagnostic Pathology | Full TextFrequency of BRAF V600E mutations in 969 central nervous system neoplasms | Diagnostic Pathology | Full Text

This study assesses the BRAF V600E mutation status in 969 intracranial neoplasms using a tissue microarray method and ... Thirty-six out of 969 (4 %) analyzed central nervous system neoplasms were immunohistochemically positive for the BRAF V600E ... Cases with primary central nervous system (CNS) tumors and metastases in advanced stages, where established therapies are ... The role of BRAF mutations in primary central nervous system tumors has been addressed by several studies that mostly showed ...
more infohttps://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-016-0506-2

UCSF Primary Malignant Central Nervous System Neoplasm Clinical Trials - San Francisco Bay Area, CaliforniaUCSF Primary Malignant Central Nervous System Neoplasm Clinical Trials - San Francisco Bay Area, California

Do you qualify for these Primary Malignant Central Nervous System Neoplasm studies? Were researching the most effective ... Primary Malignant Central Nervous System Neoplasm clinical trials at UCSF 2 research studies open to eligible people ...
more infohttps://clinicaltrials.ucsf.edu/primary-malignant-central-nervous-system

Central Nervous System Organ Benign Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsCentral Nervous System Organ Benign Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MalaCards based summary : Central Nervous System Organ Benign Neoplasm is related to central nervous system germinoma and ... MalaCards integrated aliases for Central Nervous System Organ Benign Neoplasm:. Name: Central Nervous System Organ Benign ... Pathways related to Central Nervous System Organ Benign Neoplasm according to GeneCards Suite gene sharing:. #. Super pathways ... MGI Mouse Phenotypes related to Central Nervous System Organ Benign Neoplasm:. 46 #. Description. MGI Source Accession. Score. ...
more infohttps://www.malacards.org/card/central_nervous_system_organ_benign_neoplasm

Hayworth Cancer Center | Wake Forest Baptist HealthHayworth Cancer Center | Wake Forest Baptist Health

Central Nervous System Neoplasm. Cervical Cancer. Cholangiocarcinoma. Chronic Lymphocytic Leukemia (CLL). Chronic Myelogenous ... Due to the different physician groups and hospitals within the Wake Forest Baptist system, physician services and hospital ...
more infohttps://www.wakehealth.edu/Locations/Facilities/Hayworth-Cancer-Center

External Beam Radiation | Wake Forest Baptist HealthExternal Beam Radiation | Wake Forest Baptist Health

Central Nervous System Neoplasm. Cholangiocarcinoma. Chondrosarcoma. Colorectal Cancer. Dermatofibrosarcoma Protuberans. ... Due to the different physician groups and hospitals within the Wake Forest Baptist system, physician services and hospital ...
more infohttps://www.wakehealth.edu/Treatment/e/External-Beam-Radiation

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children |...A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children |...

Neoplasms , Solid Tumors Harboring NTRK Fusion , Cancer/Tumors , Cancer (Pediatric) , Solid Tumors Habouring NTRK Fusion , A ... Clinical trial for Central Nervous System Neoplasms , Cancer , Ewings Family Tumors , ... Conditions: Central Nervous System Neoplasms , Cancer , Ewings Family Tumors , Neoplasms , Solid Tumors Harboring NTRK Fusion ...
more infohttps://www.centerwatch.com/clinical-trials/listings/84589/solid-tumors-harboring-ntrk-fusion-study-test-safety-efficacy/?section=elg&geo_lat=34.7660929&geo_lng=135.6280998&radius=10

Robotic-Assisted Surgery in Treating Patients With Spine Tumors - Full Text View - ClinicalTrials.govRobotic-Assisted Surgery in Treating Patients With Spine Tumors - Full Text View - ClinicalTrials.gov

Central Nervous System Neoplasms. Nervous System Neoplasms. Neoplasms by Site. Spinal Cord Diseases. Central Nervous System ... Neoplasm Metastasis. Spinal Cord Neoplasms. Neoplastic Processes. Neoplasms. Pathologic Processes. ... Adult Spinal Cord Neoplasm Spinal Bone Metastases Spinal Cord Metastases Procedure: therapeutic conventional surgery ...
more infohttps://clinicaltrials.gov/ct2/show/NCT01345903

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2...Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2...

Central Nervous System Neoplasms. Nervous System Neoplasms. Brain Diseases. Central Nervous System Diseases. Nervous System ... Breast Neoplasms. Neoplasm Metastasis. Neoplasms, Second Primary. Brain Neoplasms. Neoplasms by Site. Neoplasms. Breast ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT02598427?term=pertuzumab&rank=6

Assessment of Eloquent Function in Brain Tumor Patients - Full Text View - ClinicalTrials.govAssessment of Eloquent Function in Brain Tumor Patients - Full Text View - ClinicalTrials.gov

Brain Neoplasms. Central Nervous System Neoplasms. Nervous System Neoplasms. Neoplasms by Site. Brain Diseases. Central Nervous ...
more infohttps://clinicaltrials.gov/ct2/show/NCT01535430?recr=Open&cond=%22Brain+Neoplasms%22&rank=4

Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With...Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With...

Neoplasms. Central Nervous System Neoplasms. Nervous System Neoplasms. Neoplasms by Site. Brain Diseases. Central Nervous ... Nervous System Diseases. Carboplatin. Temozolomide. Thiotepa. Tretinoin. Antineoplastic Agents. Antineoplastic Agents, ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT00528437?term=ISOTRETINOIN&rank=59

Linfoma intra-ocular primário de células tipo B: relato de casoLinfoma intra-ocular primário de células tipo B: relato de caso

Keywords : Uveitis; Central nervous system neoplasms [complications]; Lymphoma, non-Hodgkin [surgery]; Paraneoplastic syndromes ... It can occur alone or can be associated with lymphoma of the central nervous system and a frequent manifestation is a posterior ...
more infohttp://www.scielo.br/scielo.php?script=sci_abstract&pid=S0004-27492007000400026&lng=en&nrm=iso&tlng=en

Evolve Resources for Pathology for the Physical Therapist Assistant, 2nd Edition - 9780323395977Evolve Resources for Pathology for the Physical Therapist Assistant, 2nd Edition - 9780323395977

Central Nervous System Neoplasms - Epilepsy - Headache - The Male Genital or Reproductive System

System - Vestibular Disorders - Laboratory Tests and ValuesSystem - The Renal and Urologic Systems - ...

more infohttps://evolve.elsevier.com/cs/product/9780323395977?role=student

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain TumorsRadiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

Nervous System Neoplasms. *Neuroblastoma. *Central Nervous System Neoplasms. .map{width:100%;height:300px;margin-bottom:15px}. ... the nervous system required. - Presence of tenascin in the tumor demonstrated by immunohistology with either a. polyclonal ...
more infohttp://www.knowcancer.com/cancer-trials/NCT00003484/

SarCNU in Treating Patients With Recurrent Malignant GliomaSarCNU in Treating Patients With Recurrent Malignant Glioma

Nervous System Neoplasms. *Central Nervous System Neoplasms. *Glioma. .map{width:100%;height:300px;margin-bottom:15px}. Name. ...
more infohttp://www.knowcancer.com/cancer-trials/NCT00036660/

Elizabeth Brooks Claus, PhD, MD | Yale School of MedicineElizabeth Brooks Claus, PhD, MD | Yale School of Medicine

Breast Neoplasms; Epidemiology; Meningioma; Neurosurgery; Statistics as Topic; Central Nervous System Neoplasms ... Claus EB: Neurosurgical management of metastases in the central nervous system. Nat Rev Clin Oncol. 2011 Dec 6; 2011 Dec 6. ... Neurosurgical management of metastases in the central nervous System Claus EB. . Nat Rev Clin Oncol 2012; 9, 79-86; published ...
more infohttp://medicine.yale.edu/intranet/facultybydept/elizabeth_claus-2.profile

Malignant Brain Tumours | SpringerLinkMalignant Brain Tumours | SpringerLink

Central Nervous System Neoplasms in Acquired Immunodeficiency Syndrome Yuen T. So, Richard L. Davis, Jay H. Beckstead ... Current Concepts of the Histopathological Classification of Tumours of the Central Nervous System ... Grading Nervous System attention brain classification genetics glioma imaging immunotherapy molecular genetics neuroscience ...
more infohttps://link.springer.com/book/10.1007%2F978-1-4471-1877-0

Stem Cell Biology in Neoplasms of the Central Nervous System :: E-book CollectionStem Cell Biology in Neoplasms of the Central Nervous System :: E-book Collection

The role of stem cells in pediatric central nervous system malignancies. - Laboratory models for central nervous system tumor ... Post a Comment for Stem Cell Biology in Neoplasms of the Central Nervous System ... Add tags for Stem Cell Biology in Neoplasms of the Central Nervous System ... This volume provides a comprehensive overview of the characteristics of CSCs, their role in central nervous system (CNS) tumors ...
more infohttp://beyond.library.tu.ac.th/cdm/ref/collection/ebook/id/14298/

Plus itPlus it

Epidemiology of primary central nervous system neoplasms. II. Case-control study. Am J Epidemiol 1970;91:467-85. ... Melean G, Sestini R, Ammannati F, Papi L. Genetic insights into familial tumors of the nervous system. Am J Med Genet C Semin ... Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J ... Pathology and genetics: tumours of the nervous system. Lyon: IARC; 2000. p. 6. ...
more infohttps://cebp.aacrjournals.org/content/16/9/1730

Advanced Search Results - Public Health Image Library(PHIL)Advanced Search Results - Public Health Image Library(PHIL)

Categories: Central Nervous System Neoplasms Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
more infohttps://phil.cdc.gov/AdvancedSearchResults.aspx?Search=Central+Nervous+System+Neoplasms&parentid=17840&catid=30367
  • Central precocious puberty (CPP) was reported in some patients with suprasellar arachnoid cysts (SAC), and SCFE (slipped capital femoral epiphysis) occurs in patients with CPP because of rapid growth and changes of growth hormone secretion. (wikipedia.org)